Study type

Study type

Not applicable

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness
Disease epidemiology
Drug utilisation
Effectiveness study (incl. comparative)

If ‘Not applicable’, further details on the study type

Interventional real-world cluster-randomised study
Study drug and medical condition

Medical condition to be studied

Chronic obstructive pulmonary disease
Asthma
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

2748
Study design details

Main study objective

To identify patients with a COPD and/or asthma diagnosis at high risk of exacerbation utilising technology to support improved disease management by primary care providers and reduce the high-cost burden of respiratory events on the health care system by preventing otherwise avoidable hospitalisations.

Outcomes

For asthma exacerbations, a 20% reduction in exacerbations is anticipated. For COPD exacerbations, a 20% reduction in exacerbations is anticipated. Time to first, and rate of, asthma-related crisis events for at-risk patients. The percentage of all registered asthma patients with an asthma-related crisis event, their rate of, and time to, first asthma-related crisis events.

Data analysis plan

The OPC Clinical Audit consists of an electronic clinical audit using secure and confidential patient data from GP sites. Patients with asthma and/or COPD including a screen for undiagnosed COPD will be included. Patient-reported outcomes will be collected for identified high-risk asthma and COPD patients. A list of patients at risk of exacerbation or that have undiagnosed COPD will be generated (re-identified) and invited to the study as part of the Audit Group. A face-to-face review of the re-identified high-risk patients with the practice nurse followed up with a consultation with the GP utilising clinical decision support advice from OPC.